Pfizer announced plans to split its generic and patent-protected drug operations into different business units -- "value" and "innovative" -- with an eye toward possibly spinning off its generic-drug business. The "value" business unit will comprise biosimilars and products set to lose patent protection through 2015. The "innovative" unit will be subdivided into one section including vaccines, oncology drugs and consumer products and another covering drugs for inflammation, immunology, cardiovascular and metabolic diseases, rare diseases, neuroscience, pain and other areas.

Full Story:

Related Summaries